Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  VBI Vaccines Inc.    VBIV   CA91822J1030

VBI VACCINES INC.

(VBIV)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/22/2020 10/23/2020 10/26/2020 10/27/2020 10/28/2020 Date
2.61(c) 2.55(c) 2.46(c) 2.51(c) 2.4 Last
4 149 707 2 593 022 3 960 233 2 519 552 3 443 280 Volume
+3.16% -2.30% -3.53% +2.03% -4.38% Change
More quotes
Financials (USD)
Sales 2020 1,31 M - -
Net income 2020 -38,2 M - -
Net Debt 2020 - - -
P/E ratio 2020 -13,8x
Yield 2020 -
Sales 2021 6,71 M - -
Net income 2021 -45,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -12,7x
Yield 2021 -
Capitalization 580 M 580 M -
Capi. / Sales 2020 444x
Capi. / Sales 2021 86,5x
Nbr of Employees 124
Free-Float 72,5%
More Financials
Company
VBI Vaccines Inc. is a development-stage biotechnology company. The Company's principal products include cytomegalovirus (CMV) Vaccine Candidate, enveloped Virus Like Particle (eVLP) Vaccine Platform and Lipid Particle Vaccine (LPV) Vaccine Platform. The Company is also engaged in the research and development (R and D) activity. The Company's subsidiaries includes Variation Biotechnologies (US), Inc. (VBI US) and... 
More about the company
Notations Surperformance© of VBI Vaccines Inc.
Trading Rating : Investor Rating :
More Ratings
All news about VBI VACCINES INC.
10/26VBI VACCINES : Presents Phase 3 Sci-B-VacŪ Data at ID Week 2020™
BU
10/15VBI VACCINES : to Present at the H.C. Wainwright Hepatitis B Virus (HBV) Mini-Co..
BU
10/08VBI VACCINES : Announces e-Poster Presentation at The Liver MeetingŪ 2020
BU
09/24VBI VACCINES : to Present at Upcoming Scientific Conferences
BU
09/21VBI VACCINES : signs agreement with Canada to develop COVID-19 vaccine by 2022
RE
09/17VBI VACCINES : Announces Biomarker Data From VBI-1901 Phase 1/2a Study in Recurr..
BU
09/14VBI VACCINES : to Present Additional Biomarker Data from VBI-1901 Phase 1/2a Stu..
BU
08/31VBI VACCINES : Sci-B-VacŪ Phase 3 Data at EASL 2020
PU
08/31VBI VACCINES : Presents Phase 3 Sci-B-VacŪ Data at EASL 2020
BU
08/26VBI VACCINES : selects two COVID-19 vaccine candidates for human trials
RE
08/26VBI VACCINES :  VBI Vaccines Announces Preclinical Coronavirus Program Data and ..
BU
08/20VBI VACCINES : Announces Multiple Phase 3 Sci-B-VacŪ Abstracts Accepted for Oral..
BU
08/05Canada signs deals with Pfizer, Moderna for experimental COVID-19 vaccines
RE
08/05Canada signs deals with Pfizer, Moderna for experimental COVID-19 vaccines
RE
08/05VBI VACCINES : Awarded Up to CAD$56 Million Contribution from Canadian Governmen..
BU
More news
News in other languages on VBI VACCINES INC.
2019VBI VACCINES : annonce la phase 2a de l'évaluation clinique du candidat-vaccin V..
2019VBI VACCINES : veröffentlicht klinische Evaluierung der Phase 2a des Krebsimpfst..
More news
Chart VBI VACCINES INC.
Duration : Period :
VBI Vaccines Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VBI VACCINES INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 6,75 $
Last Close Price 2,51 $
Spread / Highest target 259%
Spread / Average Target 169%
Spread / Lowest Target 19,5%
EPS Revisions
Managers
NameTitle
Jeffrey R. Baxter President, Chief Executive Officer & Director
Steven H. Gillis Chairman
Christopher McNulty CFO, Director & Head-Business Development
David Evander Anderson Chief Scientific Officer
Francisco Diaz-Mitoma Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
VBI VACCINES INC.72.10%580
LONZA GROUP AG63.59%47 362
SEAGEN INC.70.51%34 263
IQVIA HOLDINGS INC.1.15%30 511
CELLTRION, INC.32.04%28 321
MODERNA, INC.240.08%27 885